Plus Therapeutics presented data on its novel radioisotope rhenium-186 at the annual meeting of the Society of Nuclear Medicine & Molecular Imaging (SNMMI) in Toronto.

Link to presentation:

An oral presentation titled, “Radiation Absorbed Dose to Spinal Cord: Therapy of Leptomeningeal Metastases Using Beta-Emission Pharmaceuticals”, brief highlights:

– Data from the ReSPECT-LM clinical trial was used to evaluate the safety and potential spinal cord toxicity of beta-emission radioisotopes, including 177Lu, 131I, 186Re, 188Re, and 90Y
– Higher beta-energy emitters (i.e., 188Re and 90Y) give higher radiation absorbed doses to spinal cord with more heterogeneous radiation absorbed doses to spinal fluid
– Lower beta-energy radionuclides (177Lu, 131I, and 186Re) can largely spare the spinal cord, presenting a promising approach to minimize toxicity while delivering high doses to eradicate cancer cells

#nuclearmedicine #clinicaltrials #radiotherapy